Company: NCEL
Filing Date: 2025-02-05
Form Type: F-3
Source: 0001213900-25-010223
Chunk: 87

Company: NewcelX Ltd.
Filing Date: 2025-02-05
Form: F-3
Chunk 87
---
 and advisors may be employed by employers other than Kadimastem and may have commitments under consulting or advisory contracts with other entities that may limit their availability to Kadimastem. If Kadimastem is unable to continue to attract and retain high quality personnel, its ability to pursue its growth strategy will be limited.

Certain agreements that Kadimastem entered into with its lenders contain, and future debt agreements may contain, restrictions that may limit its flexibility in operating its business.

Kadimastem has entered into a credit facility with certain lenders which contained restrictions, such as prohibiting that Kadimastem merges into another company or change its accounting standards, that could limit its flexibility in operating its business. Documents governing its future indebtedness, or in connection with additional capital raises, if any, may contain, numerous financial and operating covenants that limit the discretion of management with respect to certain business matters. Restrictive covenants included in the above-mentioned credit facility include restrictions on, among others, Kadimastem’s ability to:

| ● | create or permit to subsist                          
 any security interest over any of its assets;        |
| ● | sell, transfer or otherwise                          
 dispose of any or its receivables on recourse terms; |
| ● | pay dividends;                                       |
| ● | buy back its own common                              
 shares;                                              |

| ● | incur or permit additional    
 indebtedness;                 |
| ● | merge or conduct any other    
 corporate reconstruction; and |
| ● | change the nature of its      
 business.                     |

Kadimastem’s ability to comply with these and other provisions of the existing debt agreements is dependent on its future performance, which will be subject to many factors, some of which are beyond its control. The breach of any negative covenants in Kadimastem’s current or future agreements could result in an event of default, as may be defined in such agreements, thereby leading to a potential default interest rate or immediate repayment of any borrowed amounts. These restrictive covenants which may be in place from time to time and a lack of compliance by Kadimastem could limit its flexibility in operating its business.

<div align='center'>60</div>

The use of any of Kadimastem’s product candidates could result in product liability or similar claims that could be expensive, damage its reputation and harm its business.

Kadimastem’s business exposes it to an inherent risk of potential product liability or similar claims. The pharmaceutical industry has historically been litigious